Natixis Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Natixis Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,267	Closed	-$2.76M	–	1536
2023 Q1	$2.76M	Sell	25,267 -111,900	-82%	-$12.4M	0.01%	857
2022 Q4	$15.6M	Sell	137,167 -23,148	-14%	-$1.92M	0.06%	355
2022 Q3	$9.92M	Sell	160,315 -66,445	-29%	-$4.64M	0.04%	436
2022 Q2	$18.1M	Sell	226,760 -2,268	-1%	-$215K	0.08%	291
2022 Q1	$24.1M	Buy	229,028 +52,675	+30%	+$5.13M	0.09%	243
2021 Q4	$19M	Buy	176,353 +6,788	+4%	+$740K	0.07%	294
2021 Q3	$18.6M	Buy	169,565 +33,063	+24%	+$3.43M	0.08%	268
2021 Q2	$12.8M	Buy	136,502 +58,577	+75%	+$5.39M	0.06%	344
2021 Q1	$7.17M	Buy	77,925 +11,299	+17%	+$953K	0.04%	478
2020 Q4	$4.87M	Buy	66,626 +1,853	+3%	+$138K	0.03%	566
2020 Q3	$5.03M	Sell	64,773 -488	-0.7%	-$33.6K	0.03%	521
2020 Q2	$3.63M	Buy	+65,261	New	+$2.79M	0.02%	612

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Natixis Advisors's HZNP Position: Q2 2023 in Review

Natixis Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 25,267 shares — an estimated $2.76M sold.

Natixis Advisors first reported a position in HZNP in Q2 2020 and held it in 12 quarters. The position peaked at $24.1M in Q1 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Natixis Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Natixis Advisors sold 25,267 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $2.76M.
Natixis Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 12 quarters.
Natixis Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $24.1M in Q1 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Natixis Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.